These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30998268)

  • 1. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
    Xu R; Yin J; Zhang Y; Zhang S
    J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ANXA3 deletion inhibits the resistance of lung cancer cells to oxaliplatin.
    Jin YF; Huang YT; Chen PF
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3741-3748. PubMed ID: 32329851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protective role of all-transretinoic acid (ATRA) against colorectal cancer development is achieved via increasing miR-3666 expression and decreasing E2F7 expression.
    Liu W; Song Y; Zhang C; Gao P; Huang B; Yang J
    Biomed Pharmacother; 2018 Aug; 104():94-101. PubMed ID: 29772445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells.
    Wang L; Li X; Ren Y; Geng H; Zhang Q; Cao L; Meng Z; Wu X; Xu M; Xu K
    Cancer Sci; 2019 May; 110(5):1609-1620. PubMed ID: 30868675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
    Wu YZ; Lin HY; Zhang Y; Chen WF
    J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annexin A3 Knockdown Suppresses Lung Adenocarcinoma.
    Liu YF; Liu QQ; Zhang YH; Qiu JH
    Anal Cell Pathol (Amst); 2016; 2016():4131403. PubMed ID: 27995049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolinderalactone sensitizes oxaliplatin-resistance colorectal cancer cells through JNK/p38 MAPK signaling pathways.
    Kwak AW; Park JW; Lee SO; Lee JY; Seo JH; Yoon G; Lee MH; Choi JS; Shim JH
    Phytomedicine; 2022 Oct; 105():154383. PubMed ID: 35987016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MiR-495/Annexin A3/P53 Axis Inhibits the Invasion and EMT of Colorectal Cancer Cells.
    Bai Z; Wang J; Wang T; Li Y; Zhao X; Wu G; Yang Y; Deng W; Zhang Z
    Cell Physiol Biochem; 2017; 44(5):1882-1895. PubMed ID: 29224019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.
    Liu W; Zhang Z; Zhang Y; Chen X; Guo S; Lei Y; Xu Y; Ji C; Bi Z; Wang K
    Cancer Biol Ther; 2015; 16(4):511-7. PubMed ID: 25778491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COPB2 gene silencing inhibits colorectal cancer cell proliferation and induces apoptosis via the JNK/c-Jun signaling pathway.
    Wang Y; Xie G; Li M; Du J; Wang M
    PLoS One; 2020; 15(11):e0240106. PubMed ID: 33211699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer.
    Du R; Liu B; Zhou L; Wang D; He X; Xu X; Zhang L; Niu C; Liu S
    Cell Death Dis; 2018 Jan; 9(2):126. PubMed ID: 29374148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells.
    Zhou T; Li Y; Yang L; Liu L; Ju Y; Li C
    Oncol Rep; 2017 Jan; 37(1):388-398. PubMed ID: 27878264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling.
    Cai J; Su L; Luo W
    Bioengineered; 2022 Jun; 13(6):14450-14459. PubMed ID: 35758246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
    Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.
    Cheraghi-Shavi T; Jalal R; Minuchehr Z
    PLoS One; 2023; 18(8):e0289535. PubMed ID: 37535601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-Suppressing Effect of Silencing of Annexin A3 Expression in Breast Cancer.
    Kim JY; Jung EJ; Park HJ; Lee JH; Song EJ; Kwag SJ; Park JH; Park T; Jeong SH; Jeong CY; Ju YT; Lee YJ; Hong SC
    Clin Breast Cancer; 2018 Aug; 18(4):e713-e719. PubMed ID: 29217453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
    Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
    Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-340-5p is a potential prognostic indicator of colorectal cancer and modulates ANXA3.
    Yang L; Men WL; Yan KM; Tie J; Nie YZ; Xiao HJ
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4837-4845. PubMed ID: 30070320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin‑resistant cell line to oxaliplatin by inhibiting excision repair cross‑complementing group 1 protein expression.
    Li JM; Jiang GM; Zhao L; Yang F; Yuan WQ; Wang H; Luo YQ
    Oncol Rep; 2019 Nov; 42(5):1725-1734. PubMed ID: 31436301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.